• 1
    Greenberger PA. Use of immunotherapy for allergic disorders. Diagnostic considerations and indications. Immunol Allergy Clin North Am 1992;12:1 12
  • 2
    Malling H-J. Sublingual immunotherapy. Clin Exp Allergy 1996;26:1228 1231
  • 3
    Casanovas M, Guerra F, Moreno C, Miguel R, Maranon F, Daza JC. Double-blind, placebo-controlled clinical trial of preseasonal treatment with allergenic extracts of Olea europaea pollen administered sublingually. J Investig Allergol Clin Immunol 1994;4:305 314
  • 4
    Clavel R, Bousquet J, André C. Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five grass pollen extract in rhinitis. Allergy 1998;53:493 498
  • 5
    Creticos PS, Naclerio RM, Adkinson NF, Norman PS. Efficacy, safety and kinetics of oral ragweed immunotherapy in the treatment of allergic seasonal rhinitis. J Allergy Clin Immunol 1990;85:165
  • 6
    Leng X, Fu YX, Ye ST, Duan SQ. A double-blind trial of oral immunotherapy for Artemisia pollen asthma with evaluation of bronchial response to the pollen allergen and serum-specific IgE antibody. Ann Allergy 1990;64:27 31
  • 7
    Feliziani V, Lattuada G, Partmiani S, Dall'aglio PP. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double-blind study. Allergol Immunopathol (Madr) 1995;23:224 230
  • 8
    Giovane AL, Bardare M, Passalacqua G, et al. A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients. Clin Exp Allergy 1994;24:53 59
  • 9
    Passalacqua G, Albano M, Fregonese L, et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998;351:629 632
  • 10
    Sabbah A, Hassoun S, Le Sellin J, André C, Sicard H. A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 1994;49:309 313
  • 11
    Scadding GK & Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mites. Clin Allergy 1986;16:483 491
  • 12
    Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mites. A double-blind study. Allergol Immunopathol (Madr) 1990;18:277 284
  • 13
    Troise C, Voltolini S, Canessa A, Pecora S, Negrini AC. Sublingual immunotherapy in Parietaria pollen induced rhinitis: a double-blind study. J Investig Allergol Clin Immunol 1995;5:25 30
  • 14
    Van Niekerk CH & De Wet JI. Efficacy of grass-maize pollen oral immunotherapy in patients with seasonal hay-fever: a double-blind study. Clin Allergy 1987;17:507 513
  • 15
    Vourdas D, Syrigou E, Potamianou P, et al. Double-blind placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998;53:662 672
  • 16
    Möller C, Dreborg S, Lanner A, Björkstén B. Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. Allergy 1986;41:271 279
  • 17
    Nelson HS, Oppenheimer J, Vatsia GA, Buchmeier A. A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol 1993;92:229 236
  • 18
    Urbanek R & Gehl R. Efficacy of oral hyposensitization treatment in house dust mite allergy. Monatsschr Kinderheilkd 1982;130:150 152
  • 19
    Aas K. Heterogeneity of bronchial asthma. Allergy 1981;36:3 14
  • 20
    Bousquet J, Hejjaoui A, Dhivert H, Clauzel AM, Michel FB. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. III. Systemic reactions during the rush protocol in patients suffering from asthma. J Allergy Clin Immunol 1989;83:797 802
  • 21
    Haynes RC. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones Goodman, Gilman The pharmacological basis of therapeutics .. London: McGraw-Hill, 19901431 1462
  • 22
    Quoix E, Le Mao J, Hoyet C, Pauli G. Prediction of mite allergen levels by guanine measurements in house-dust samples. Allergy 1993;48:306 309
  • 23
    Ware JE, Sherbourne CD, Davies AR. Developing and testing the MOS 20-Item Short-Form Health Survey: a general population application StewartAL, WareJE Measuring functioning and well-being: the medical outcomes study approach .. Durham, NC: Duke University Press, 1992277 290
  • 24
    Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT Statement. JAMA 1996;276:637 639
  • 25
    Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children. JAMA 1998;279:1181 1186
  • 26
    Sheffer AL. International consensus report on the diagnosis and management of asthma. Clin Exp Allergy 1992;22 (Suppl 1):
  • 27
    Turner MO, Taylor D, Bennett R, Fitzgerald JM. A randomized trial comparing peak expiratory flow and symptom self-management plans for patients with asthma attending a primary care clinic. Am J Respir Crit Care Med 1998;157:540 546
  • 28
    Van Wilsen EJG, Van Hoogstraten IMW, Brevé J, Scheper RJ, Kraol G. Dendritic cells of the oral mucosa and the induction of oral tolerance. A local affair. Immunology 1994;83:128 132
  • 29
    Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Müller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995;154:187 194
  • 30
    McHugh SM, Deighton J, Stewart AG, Lachmann PJ, Ewan PW. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy 1995;25:828 838